Revenue Comparison: Eli Lilly's GLP-1 Growth vs. Bristol Myers Squibb's Steady Performance
Eli Lilly (LLY) is experiencing explosive revenue growth driven by its metabolic health portfolio, specifically the GLP-1 drugs Mounjaro and Zepbound. Recent data shows quarterly revenue climbing from $11.4 billion in Q3 2024 to a projected $23.0 billion by Q2 2026. This surge is supported by significant year-over-year increases in sales for its obesity and diabetes treatments, alongside the recent launch of the oral formulation Foundayo. In contrast, Bristol Myers Squibb (BMY) maintains a more stable revenue profile, primarily supported by oncology and cardiovascular treatments such as Opdivo and Eliquis. While BMY lacks a GLP-1 competitor in its current lineup, it has recently expanded regulatory approvals for cardiovascular drugs and entered an AI partnership with Nvidia to accelerate drug discovery. Investors face a valuation gap, with Lilly trading at a significant premium compared to the more conservatively valued Bristol Myers Squibb.
Tickers: $ATAI $BMY $LLY $NVDA
Topics: acquisition FDA approval pharmaceutical industry quarterly earnings revenue growth strategic partnership
Read the full article at Motley Fool
Part of the story Comparative Revenue Analysis of AbbVie and Bristol Myers Squibb (3 articles)